DKSC (Dakshidin) EBIT per Share: $ (TTM As of Sep. 2023)


What is Dakshidin EBIT per Share?

Dakshidin DKSC EBIT per Share is $ as of Sep. 2023.

Dakshidin's EBIT per Share for the three months ended in Sep. 2023 was $0.00. Dakshidin does not have enough years/quarters to calculate its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Dakshidin's EBIT per Share or its related term are showing as below:

DKSC's 3-Year EBIT Growth Rate is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.65
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Dakshidin's EBIT for the three months ended in Sep. 2023 was $-0.00 Mil.

Dakshidin  (OTCPK:DKSC) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Dakshidin EBIT per Share Related Terms

Dakshidin EBIT per Share Historical Data

* Premium members only.

The historical data trend for Dakshidin's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dakshidin EBIT per Share Chart

Dakshidin Annual Data
Trend
EBIT per Share

Dakshidin Quarterly Data
Mar19 Mar20 Sep22 Sep23
EBIT per Share 0.00 0.00 0.00 0.00

Dakshidin EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Dakshidin's EBIT per Share for the fiscal year that ended in . 20 is calculated as

EBIT per Share(A: . 20 )
=EBIT/Shares Outstanding (Diluted Average)
=/0
=N/A

Dakshidin's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

EBIT per Share(Q: Sep. 2023 )
=EBIT/Shares Outstanding (Diluted Average)
=-0.002/2578.760
=-0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of $ mean?
Dakshidin (DKSC) has a EBIT per Share of $ as of Sep. 2023. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Dakshidin and its competitors.
Is Dakshidin's EBIT per Share too high?
Dakshidin's current EBIT per Share is $.
How does Dakshidin's EBIT per Share compare to ECEZ and AFBG?
Dakshidin's EBIT per Share of $ can be compared against companies in the Drug Manufacturers industry. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Dakshidin and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dakshidin's current EBIT per Share is $. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dakshidin stock overvalued right now?
Dakshidin (DKSC) has a current EBIT per Share of $. The current EBIT per Share is $. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Dakshidin (DKSC), the current EBIT per Share is $ as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Dakshidin Business Description

Address 508 Locust Street, Lockport, NY, USA, 14094
Dakshidin Corp is a Cannabis-based medical product company. The company operates through its online e-commerce store laughingfrogs.com. The company is composed of four synergistic entities: Laughing Frogs, an online sales portal for the company's CBD products; Laughing Frogs Nutraceutical the online sales portal for all non-CBD hemp oil products and its proprietary nutraceutical products, company's new PPE division and Runnymede Farms, a company that is focused on the cultivation of specifically grown Hemp plants. through its growing operations and Joint Ventures with established growers.